BioCentury | Feb 8, 2017
Clinical News

DCVax-L: Ph III ongoing

...lifted the partial clinical hold on a double-blind, placebo-controlled, international Phase III trial evaluating intradermal DCVax-L...
...the trial (see BioCentury, Jan. 9 ). Northwest Biotherapeutics Inc. (OTCQB:NWBO), Bethesda, Md. Product: DCVax-Brain (DCVax-L...
...PFS); overall survival (OS) and time to disease progression Status: Phase III ongoing Milestone: NA Julian Zhu DCVax-Brain DCVax-L Northwest...
BioCentury | Jan 5, 2017
Clinical News

DCVax-L: Ph III ongoing

...patients of a planned 348 into a double-blind, placebo-controlled, international Phase III trial of intradermal DCVax-L...
...dialogue” with FDA but did not disclose the reason for the partial hold. Patients receive DCVax-L...
...16, 32, 48, 72, 96 and 120. Northwest Biotherapeutics Inc. (OTCQB:NWBO), Bethesda, Md. Product: DCVax-Brain (DCVax-L...
BioCentury | Jun 29, 2015
Clinical News

DCVax-Direct: Additional Phase I/II data

Northwest Biotherapeutics said 27 of 39 evaluable patients with advanced, inoperable solid tumors who received intratumoral DCVax-Direct in the Phase I portion of an open-label, U.S. Phase I/II trial were alive up to 18 months...
BioCentury | Mar 30, 2015
Clinical News

DCVax-Brain: Clinical trial data

...Data from 51 evaluable patients with newly diagnosed GBM showed that DCVax-L led to a median...
...>=1 cm in size or tumor growth >=25% both at baseline and at 2 months, DCVax-L...
...of daily radiotherapy and chemotherapy. Northwest Biotherapeutics Inc . (NASDAQ:NWBO), Bethesda, Md. Product: DCVax-Brain ( DCVax-L...
BioCentury | Mar 28, 2015
Clinical News

Northwest gains on GBM survival data

...DCVax-L ), and instead were treated in a separate study arm. In that "informational arm," DCVax-Brain...
...and instead were treated in a separate study arm. In that "informational arm," DCVax-Brain (DCVax-L...
BioCentury | Sep 22, 2014
Clinical News

DCVax-L regulatory update

...The U.K.'s Department of Health granted DCVax-L from Northwest Biotherapeutics promising innovative medicine (PIM) designation to...
...advice from the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) and NICE during development. DCVax-L...
...designation in the U.S. and EU. Northwest Biotherapeutics Inc. (NASDAQ:NWBO), Bethesda, Md. Product: DCVax-L ( DCVax-Brain...
BioCentury | Jul 28, 2014
Clinical News

DCVax-Direct: Completed Phase I enrollment

Northwest Biotherapeutics completed enrollment of 36 patients in the Phase I portion of an open-label, U.S. Phase I/II trial evaluating DCVax-Direct. Patients are receiving 6 intratumoral injections of DCVax-Direct on day 0, 7 and 14...
BioCentury | Jun 2, 2014
Clinical News

DCVax-Direct: Preliminary Phase I/II data

Preliminary data from 19 patients with advanced, inoperable solid tumors who have received >=3 injections of DCVax-Direct in the Phase I portion of an open-label, U.S. Phase I/II trial showed that 8 patients had stable...
BioCentury | Jun 2, 2014
Finance

Highlights of weekly biotech stock moves

Regulatory milestones Acura Pharmaceuticals Inc. (NASDAQ:ACUR) lost $0.17 (14%) to $1.06 last week after saying FDA advised the company that data from the Phase II Study 301 are "insufficient to support an intranasal abuse deterrence...
BioCentury | Mar 17, 2014
Clinical News

DCVax-L: Phase III ongoing

...Northwest Biotherapeutics said a DSMB recommended continuation of a double-blind, international Phase III trial evaluating DCVax-L...
...data. Patients with newly diagnosed GBM indicated for surgery are receiving 2 intradermal injections of DCVax-L...
...designation in the U.S. and EU. Northwest Biotherapeutics Inc. (NASDAQ:NWBO), Bethesda, Md. Product: DCVax-L ( DCVax-Brain...
Items per page:
1 - 10 of 72